An Overview on fast Disintegrating Sublingual Tablets
Keywords:
Angina, Dysphagia, Improved bioavailability, Sublingual delivery, TechniqueAbstract
The demand of fast disintegrating tablets has been growing during the last decade, due to the characteristics of fast disintegrating sublingual tablets for the potential emergency treatment. In terms of permeability, the sublingual area of the oral cavity (i.e, the floor of the mouth) is more permeable than the buccal (cheek) area, which in turn is more permeable than the palatal (roof) of the mouth. Drug delivery through the oral mucous membrane is considered to be a promising alternative to the oral route. Fast disintegrating sublingual tablets may lead to significant improvements over current treatment options for specific patient group, for instance pediatric and geriatric patients. This review highlights the mechanism of sublingual absorption, factors affecting sublingual absorption, formulation techniques, types of sublingual tablets, advantages, evaluation parameters and commercially available sublingual dosage forms.
References
. Birudaraj R, Berner B, Shen S, Li X. Buccal permeation of Buspirone: Mechanistic studies on transport pathways. J Pharm Sci 2005 ; 94: 70-78
. Ishikawa T, Koizumi N, Mukai B, et al. Pharmacokinetics of acetaminophen from rapidly disintegrating compressed tablets prepared using microcrystalline cellulose(PH-M-06) and spherical sugar granules. Chem Pharm Bull (Tokyo). 2001;49: 230-232
. Price TM, Blauer KL, Hansen M, Stanczyk F, Lobo R, Bates GW. Single dose pharmacokinetics of sublingual versus oral administration of micronized 17 beta estradiol. Obstet Gynecol. 1997; 89:340-345.
. Kurosaki Y, Takatori T, Nishimura H, Nakayama T, Kimura T. Regional variation in oral mucosal drug absorption permeability and degree of keratinization in hamster oral cavity. Pharm Res 1991;8:1297-1301
. Shailesh Sharma.‟ New generation of tablet: Rapid dissolving tablet.”Pharmainfo.net 2008; 6(1).
. Shahid M, Walker GB, Zorn SH, Wong EH. Asenapine: A novel psychopharmacologic agent with a unique human receptor signature.J Psychopharmacol.2009; 23(1):65-73. [PUBMED].
. Otero ML, Claros NM. Manidipine versus enalapril monotherapy in patients with hypertension and type-2 diabetes mellitus: A multicancer randomized double blend 24 week studies. Clinical Therapy 2005; Feb; 27(2): 166-173.
. Watkins KD, Boettger RF. Use of sublingual tacrolimus in lung- transplant patient’s recipients. J Heart Lung Transplant 2012. Feb; 31(2): 127-132[PUBMED].
. Romero I, et al. Sublingual administration of tacrolimus in renal transplant patients. J Clinical Pharm Therapy 2008 Feb.; 33(1): 87-9. [PUBMED].
. Uberall MA, Muller-schwefe GH. Sublingual Fentanyl ODT in daily practice: efficacy, safety and tolerability in patients with breakthrough cancer pain. Current Medical Research Opinion 2011 July; 27(7): 1385-94. [PUBMED].
. Owen RT. Novel Zolpidem formulations. Drugs Today (Barc) 2009; 45(5): 395-400.
. Stanler L, Danjou P, Luthringer R. A new sublingual formulation of Zolpidem for the treatment of sleep- onset insomnia. Expert Rev Neurotherapy 2012.12(2):141-53.[PUBMED].
. Paech MJ, Bloor M, Schuq SA. New formulations of Fentanyl for acute- pain management. Drugs Today (Barc) 2012; 48(2): 119-32. [PUBMED].
. Khan RU, EL-Rafaey H.Pharmacokinetics and adverse effects profile of rectally administered Misoprostol in the third stage of labor. Obstet Gynecol 2003; 101:968-74. [PUBMED].
. Tang OS et al. pharmacokinetics of different routes of administration of Misoprostol. Hum Reprod 2002; 17:332-6[PUBMED].
. Hofmeyr GJ, Gulmezoglu AM, Novikora N et al. Misoprostol to prevent and treat PPH: A systematic review and meta- analysis of maternal deaths and dose-related effects. Bull World Health Organ 2009; 87: 666-77[PUBMED].
. Doggrell SA. Which is the best primary medication for long- term smoking cessation- nicotine replacement therapy, buproprion or vareniciline? Expert Opinion Pharmaco Therapy 2007; 8 (17): 2903-15. [PUBMED].
. Shojaie AH. Buccal mucosa as a route for systemic drug delivery: A review. J Pharm Sci 1998; (1):15-30
. J.L.Herrera, M.F. Lyons, L.F. Johnson. Saliva; its role in health and disease.J.Clin.Gastroenterol.10 (1998) 569-578.
. B.L.Slomiany, V.L Murty, J. Piotrowski, A.Slomiany. Salivary mucins in oral mucosal defence. Gen.Pharmac.27 (1996)761-771.
. Boer D et al. Drug absorption by sublingual and rectal routes. British J Anaesthesia 1984; 56:69-82.
. Al- Ghananeem AM, Malkawi AH, Crooks PA. Effect of ph on sublingual absorption of oxycodone hydrochloride. AAPS PharmSciTech 2006; 7(1): Article 23.
. Rubinstein NH. 2000 Tablets In; “Aulton”, M.E(Ed), Pharmaceutics, the Science of Dosage Form Design Churchill Livingstone, Edinburgh London on Melbourne and New York, Page 305.
. Bhati R, Nagrajan RK. A detailed review on oral mucosal drug delivery system. IJPSR 2012; Vol3 (1):659-681.
. Richman MD, Fox D, Shangraw RF. Prepration and stability of glyceryl trinitrate sublingual tablets prepared by direct compression. J Pharm Sci 1965; 54(3):447-451.
. Mary Elizabeth RN, Martelli BS. Sublingual and buccal medication administration. Encyclopedia of nursing and allied health, 20050229.
. Lea L. Sublingual administration. Colon health1996; 13.
. Seager H. Drug delivery products and zydis fast dissolving dosage form. J Pharm Pharmacol, 1998, 50:375-382.
. Bradoo R, Shahani S, Deewan B, Sudarshan S. Fast dissolving drug delivery system. J Am Med Assoc India, 2001; 4(10):27-31.
. D Harris, Johnson JR. Drug delivery through the mucous membrane of the oral cavity.J Pharm .Sci.81 (1992)1-10.
. Duchene D, Touchard F, Peppar N.A. Pharmaceutical and medical aspects of bioadhesive systems for drug administration. Drug Dev. Ind.Pharm 1988; 14:283-318.
. Sheeba FR. Formulation and evaluation of nifedipine sublingual tablets. Asian J Pharmac Clin Res, 2(2009)44-48.
. Rameshwari S, Anandi J. Formulation and evaluation of nifedipine sublingual tablets. Asian Journal of Pharmacy and Clinical research.2009; 2(3):41-48.
. Allen LV. Rapid dissolves technology: an interview with Lloyd V.Allen. Journal of Pharmaceutical Technology.2003;7:449-450
. Mukesh P Ratnaparkhi, Dr G.P. Mohanta, Dr Lokesh Upadhayay.‟Review on: rapid dissolving tablet”. Journal of Pharmacy research, 2009.2(1).
. Jayasukh J Hirani, Dhawal A Rathod, Kantilal R Vadalia. “Orally disintegrating tablets: A Review”. Tropical Journal of Pharmaceutical Research, 2009; 8(2):161-172.
. Sastry SV, Nyshadham JR, Fixja.Recent technological advances in oral drug delivery; A Review. Pharm .Sci.Technol.Today (2000)3(4):138-145.
. Brown D. Orally disintegrating tablets-taste over speed. Drug delivery technol. (2003)3(6):58-61.
. Habib W, Khan Karir, Hontz J: Fast dissolve drug delivery systems.Crit. Rev.Ther.Drug (2000)17(1):61-72.
. Yourong Fu, Shicheng Yang, Seong Hoon Jeong et al.‟Orally rapid disintegrating tablets; Developments, Technologies, Taste-masking and Clinical studies.” Critical reviews™ in Therapeutic Drug Carrier Systems, 2004.21(6):433-475.
. Patel PB. Fast dissolving drug delivery systems: An Update.Pharmainfo.net 2006, www.Pharmainfo.net.
. Lachman L, Liberman A and King JL. Tablets: The theory and practice of industrial pharmacy, (3rd edition), Varghese publishing house, 1987, 296-300.
. Ketan A.Mehta, Serpil Kislalioglu M et al. Multi-unit controlled release system of nifedipine and nifedipine: Pluronic® F-68 Solid dispersion: Characterization of release mechanisms, Drug Dev Ind Pharm.2002; 28 Suppl 3:275-285.
. Indian Pharmacopoeia. Ministry of Health and Family Welfare, Govt. of India. The Controller of Publications. New Delhi.1996.
. Yunxia B, Sunada H, Yonezawa Y and Danjok. Evaluation of rapid disintegrating tablets prepared by direct compression method, Drug. Dev.Ind.Pharm. 25(5), 1999,571.
. Bi Y, Sunada H, Yonezawa Y, Danjok, Otoska A, lida K. Prepration and evaluation of a compressed tablet rapidly disintegrating in the oral cavity. Chem Pharm Bull (Tokyo).1996; 44:212.
